Titan Pharmaceuticals Stock In The News

TTNP Stock  USD 7.16  0.22  2.98%   
The tone or emotional content of news articles related to Titan Pharmaceuticals can affect its prices. Positive news sentiment can lead to an increase in demand for Titan Pharmaceuticals' stock, while negative news sentiment can lead to a decrease in demand. Our overall analysis of Titan Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Titan Pharmaceuticals. The specific impact of Titan Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Titan Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Titan Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Titan Pharmaceuticals Backtesting and Titan Pharmaceuticals Hype Analysis.
To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.

Titan Pharmaceuticals Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors
https://www.globenewswire.com/news-release/2023/10/16/2761085/0/en/Titan-Pharmaceuticals-Announces-Appointment-of-Dato-Seow-Gim-Shen-and-Brynner-Chaim-to-the-Company-s-Board-of-Directors.html
 Neutral
Macroaxis News: globenewswire.com
Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock
https://www.globenewswire.com/news-release/2023/09/18/2744665/0/en/Titan-Pharmaceuticals-Announces-9-5-Million-Private-Placement-of-Convertible-Preferred-Stock.html
 Bullish
Macroaxis News: globenewswire.com
Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets
https://www.globenewswire.com/news-release/2023/07/27/2712070/0/en/Titan-Pharmaceuticals-Announces-Sale-of-Certain-ProNeura-Assets.html
 Bullish
Macroaxis News: globenewswire.com
Titan Pharmaceuticals Provides Shareholder Update
https://www.globenewswire.com/news-release/2022/12/15/2574394/0/en/Titan-Pharmaceuticals-Provides-Shareholder-Update.html
 Bullish
Macroaxis News: globenewswire.com
UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.
https://www.globenewswire.com/news-release/2022/12/12/2571764/0/en/UPDATE-Titan-Pharmaceuticals-Inc-Announces-Licensing-Agreement-with-Ocular-Therapeutix-Inc.html
 Bullish
Macroaxis News: globenewswire.com
Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.
https://www.globenewswire.com/news-release/2022/12/12/2571657/0/en/Titan-Pharmaceuticals-Inc-Announces-Licensing-Agreement-with-Ocular-Therapeutix-Inc.html
 Bullish
Macroaxis News: globenewswire.com
Activist Investing Nominates Slate of Hi...
https://www.globenewswire.com/news-release/2022/07/11/2477242/0/en/Activist-Investing-Nominates-Slate-of-Highly-Qualified-Director-Candidates-for-Election-to-the-Board-of-Directors-of-Titan-Pharmaceuticals-at-Upcoming-Special-Meeting-of-Stockholde.html
 Bullish
Macroaxis News: globenewswire.com
Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.
https://www.globenewswire.com/news-release/2022/06/10/2460451/0/en/Activist-Investing-Discloses-9-9-Ownership-Interest-in-Titan-Pharmaceuticals-Inc.html
 Bullish
Macroaxis News: globenewswire.com
Activist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc.
https://www.globenewswire.com/news-release/2022/04/25/2428455/0/en/Activist-Investing-Announces-5-6-Ownership-Interest-in-Titan-Pharmaceuticals-Inc.html
 Bullish
Yahoo News
Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market
https://finance.yahoo.com/news/titan-pharmaceuticals-announces-pricing-5-134500770.html
 Bullish

Titan Pharmaceuticals Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Titan and other traded companies coverage. We help investors stay connected with Titan headlines for the 29th of March to make an informed investment decision based on correlating the impacts of news items on Titan Stock performance. Please note that trading solely based on the Titan Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Titan Pharmaceuticals' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Titan Pharmaceuticals investors visualize upcoming and past events in order to time the market based on Titan Pharmaceuticals noise-free hype analysis.
Titan Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Titan earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Titan Pharmaceuticals that are available to investors today. That information is available publicly through Titan media outlets and privately through word of mouth or via Titan internal channels. However, regardless of the origin, that massive amount of Titan data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Titan Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Titan Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Titan Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Titan Pharmaceuticals alpha.

Titan Largest EPS Surprises

Earnings surprises can significantly impact Titan Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-11-10
2022-09-30-0.21-0.180.0314 
2023-03-31
2022-12-31-0.22-0.180.0418 
2022-08-17
2022-06-30-0.26-0.180.0830 
2021-11-15
2021-09-30-0.35-0.190.1645 
2021-08-16
2021-06-30-0.35-0.170.1851 
2020-11-16
2020-09-30-1.05-1.5-0.4542 
View All Earnings Estimates

Titan Pharmaceuticals Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Titan Pharmaceuticals Stock. Current markets are strongly bullish. About 72% of major world exchanges and indexes are currently up. See today's market update for more information.
Macroaxis News
26th of March 2024
Acquisition by Joseph Akers of 25000 shares of Titan Pharmaceuticals at 4.02 subject to Ru...
at MacroaxisInsider 
zacks News
25th of March 2024
Why American Axle Manufacturing is a Top Value Stock for the Long-Term
at zacks.com 
businesswire News
20th of March 2024
Arrow Electronics Introduces IT Distributions First AI Companion to Supercharge Cloud Busi...
at businesswire.com 
Gurufocus Stories at Macroaxis
20th of March 2024
Insider Sell CFO Joseph Corso Sells 14,105 Shares of nLight Inc
at gurufocus.com 
Gurufocus Stories at Macroaxis
20th of March 2024
Director David Wilson Sells 8,000 Shares of Modine Manufacturing Co
at gurufocus.com 
news
19th of March 2024
Blue Hat Interactive Entertainment Technology Announces Corporate Refocus into AI Financia...
at kalkinemedia.com 
benzinga news
18th of March 2024
INVESTIGATION The MA Class Action Firm Continues Investigating the Merger TGAN, HMST, KNTE
at benzinga.com 
zacks News
15th of March 2024
Tesla to Produce Semi Truck at Gigafactory Berlin
at zacks.com 
Google News at Macroaxis
13th of March 2024
StockNews.com Initiates Coverage on Titan Pharmaceuticals - Defense World
at news.google.com 
Simply Wall St News at Macroaxis
11th of March 2024
Independent Director Of Modine Manufacturing Sold 33 percent Of Their Shares
at simplywall.st 
news
6th of March 2024
Acquisition by Greenberg Eric Howard of 25000 shares of Titan Pharmaceuticals at 1.52 subj...
at Greenberg Eric Howard 
Google News at Macroaxis
6th of March 2024
NLight Q3 Earnings Snapshot - Barchart
at news.google.com 
Google News at Macroaxis
5th of March 2024
Titan Pharmaceuticals Receives New Coverage from Analysts at StockNews.com - Defense World
at news.google.com 
Yahoo News
4th of March 2024
Are You a Value Investor This 1 Stock Could Be the Perfect Pick
at finance.yahoo.com 
news
1st of March 2024
Arrow Electronics, Inc. Insider Sells 221,274.00 in Stock
at thelincolnianonline.com 
insidermonkey News
29th of February 2024
Payment of 481 shares by James Nias of NLIGHT subject to Rule 16b-3
at insidermonkey.com 
Investing News at Macroaxis
27th of February 2024
UBS raises American Axle to neutral with a 7 price target
at investing.com 
zacks News
22nd of February 2024
NLight Reports Q4 Loss, Tops Revenue Estimates
at zacks.com 
Google News at Macroaxis
21st of February 2024
Should You Buy Transphorm Technology Inc in Semiconductor Equipment Materials Industry - I...
at news.google.com 
Yahoo News
9th of February 2024
Arrow Electronics, Inc. Q4 2023 Earnings Call Transcript
at finance.yahoo.com 
Yahoo News
25th of January 2024
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
at finance.yahoo.com 
Google News at Macroaxis
23rd of January 2024
Bilibili Stock , Quotes and News Summary - Benzinga
at news.google.com 
seekingalpha News
9th of January 2024
TTNP, SLDB and WRAP among mid-day movers
at seekingalpha.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Titan Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Titan Pharmaceuticals' short interest history, or implied volatility extrapolated from Titan Pharmaceuticals options trading.
When determining whether Titan Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Titan Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Titan Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Titan Pharmaceuticals Stock:
Check out Titan Pharmaceuticals Backtesting and Titan Pharmaceuticals Hype Analysis.
To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Complementary Tools for Titan Stock analysis

When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Is Titan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Titan Pharmaceuticals. If investors know Titan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Titan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.20)
Revenue Per Share
0.409
Quarterly Revenue Growth
(0.96)
Return On Assets
(0.61)
Return On Equity
(1.06)
The market value of Titan Pharmaceuticals is measured differently than its book value, which is the value of Titan that is recorded on the company's balance sheet. Investors also form their own opinion of Titan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Titan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Titan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Titan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Titan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Titan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Titan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.